

SCOUT[®] REPORT



News and Views on Surgical Guidance
and Breast Tumor Localization



Over 265,000 patients have benefited from SCOUT Wire-Free Radar Localization

SCOUT has helped more patients globally than any other wire-free localization device.

[LEARN MORE](#)

GAME-CHANGING TECHNOLOGY GETS ITS OWN PODIUM IN THE OR

After numerous observations concerning limited space in the OR for SCOUT console placement, we designed a solution. The state-of-the-art cart that has been built exclusively for the SCOUT system.

[SEE THE CART](#)



IMPROVED SCOUT PERFORMANCE

To enhance our market-leading technology, we've introduced a new design to make our reflector more robust with improved cautery resistance.

[DISCOVER MORE](#)



SCOUT EXPANDS CLINICAL PUBLICATIONS

With over 65 clinical publications, SCOUT is the most widely studied wire-free localization technology on the market. Take a look at 10 new studies added in 2021, including two from Europe.



[READ MORE](#)

MERIT PARTNERS WITH BREASTCANCER.ORG



For the third year in a row, Merit Oncology partnered with BreastCancer.org to advocate the importance of mammography


screening in detecting breast cancer at its earliest stages.

[READ MORE](#)

THINK WIRE-FREE™ EDUCATIONAL OPPORTUNITIES

We hosted 13 webinars with over 1300 registrants and 300 attendees.

[DISCOVER THE OPPORTUNITIES](#)



SCOUT SPHERE OF INFLUENCE EXPANDS TO AUSTRALIA



“SCOUT localization for the surgeon is so intuitive to use. It has saved us so much time as an institution.”

— Professor Cindy Mak
Chris O'Brien Lifehouse

Recent adoption by several of Australia's Key Opinion Leaders is testament to SCOUT's precision and ease of use for the localization of breast lesions and axillary nodes. SCOUT is now available at Specialist Breast Cancer Surgery and Chris O'Brien Lifehouse.

SCOUT PARTICIPATES IN IBRA-NET AND ATNEC STUDIES

The IBRA-NET/SCOUT Radar Localisation Study NOW recruiting.

Merit Oncology is pleased to announce its support for, and participation in, The IBRA-NET International Audit of localisation techniques for breast lesions and axillary node marking.

REGISTER NOW!

- Joining the study provides:
- Access to real-time data
- Peer and comparative insights
- Access to breast localisation solutions
- Early adoption and early feedback
- Opportunity for shared learning
- Support for clinical research
- Support for clinical research

Merit Oncology is participating in the iBRA-NET International Audit of localization techniques for breast lesions and axillary node marking.

[REGISTER NOW](#)

Strategies for Axillary Node Marking and Identification
Session 1 - 19th November 2021

Merit Oncology is participating in the ATNEC Breast Cancer Study and a webinar covering "Strategies for Axillary Node Marking and Identification".

[VIEW WEBINAR](#)



Have Questions?
EMAIL US AT alisoviejoinfo@merit.com



Understand. Innovate. Deliver.™

merit.com

Merit Medical Systems, Inc.
1600 West Merit Parkway
South Jordan, Utah 84095
1.801.253.1600
1.800.35.MERIT

Merit Medical Europe, Middle East & Africa (EMEA)
Amerikalaan 42, 6199 AE
Maastricht-Airport
The Netherlands
+31 43 358 82 22

Merit Medical Ireland Ltd.
Parkmore Business Park West
Galway, Ireland
+353 (0) 91 703 733